Bidirectional interaction of valproate and lamotrigine in healthy subjects

Clinical Pharmacology and Therapeutics

Volumn 60, Issue 2, 1996, Pages 145-156

  Anderson, Gail D ^a   Yau, Martin K ^b   Gidal, Barry E ^b   Harris, Stuart J ^b   Levy, René H ^b   Lai, Allen A ^b   Wolf, Karen B ^b   Wargin, William A ^b   Dren, Anthony T ^b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DRUG METABOLITE; LAMOTRIGINE; VALPROATE SEMISODIUM; VALPROIC ACID;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG METABOLISM; DRUG URINE LEVEL; GAS CHROMATOGRAPHY; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; MASS SPECTROMETRY; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; STEADY STATE; VERTIGO; VOLUNTEER;

ANALYSIS OF VARIANCE; ANTICONVULSANTS; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; HALF-LIFE; HUMANS; MALE; REFERENCE VALUES; TIME FACTORS; TRIAZINES; VALPROIC ACID;

EID: 0029909431     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(96)90130-7     Document Type: Article

References (35)

1. Binnie CD, Debets RMC, Engelsman M, Meijer JW, Meinardi H, Overweg J, et al. Double-blind crossover trial of lamotrigine (Lamictal) as add-on therapy in intractable epilepsy. Epilepsy Res 1989;4:222-9.
2. Jawad S, Richens A, Goodwin G, Yuen WC. Controlled trial of lamotrigine (Lamictal) for refractory partial seizures. Epilepsia 1989;30:356-63.
3. Loiseau P, Yuen AWC, Duché B, Ménager T, Arné-Bes MC. A randomised double-blind placebo-controlled crossover add-on trial of lamotrigine in patients with treatment-resistant partial seizures. Epilepsy Res 1990;7:136-45.
4. Sander JWAS, Patsalos PN, Oxley JR, Hamilton MJ, Yuen WC. A randomized double-blind placebo-controlled add-on trial of lamotrigine in patients with severe epilepsy. Epilepsy Res 1990;6:221-6.
5. Matsuo F, Bergen D, Faught E, Messenheimer JA, Dren AT, Rudd GD, et al. Placebo-controlled study of the efficacy and safety of lamotrigine in patients with partial seizures. Neurology 1993;43:2284-91.
6. Messenheimer J, Ramsay RE, Willmore LJ, Leroy RF, Zielinski JJ, Mattson R, et al. Lamotrigine therapy for partial seizures: a multicenter, placebo-controlled, double-blind, crossover trial. Epilepsia 1994;35:113-21.
7. Cohen AF, Land GS, Breimer DD, Yuan WC, Winton C, Peck AW. Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans. Clin Pharmacol Ther 1987;42:535-41.
8. Doig MV, Clare RA. Use of thermospray liquid chromatography-mass spectrometry to aid in the identification of urinary metabolites of a novel antiepileptic drug, lamotrigine. J Chromatogr 1991;554:181-9.
9. Sinz MW, Remmel RO. Isolation and characterization of a novel quarternary ammonium-linked glucuronide of lamotrigine. Drug Metab Dispos 1991;19: 149-53.
10. Posner J, Webster H, Yuen WC. Investigation of the ability of lamotrigine, a novel antiepileptic drug, to induce mixed function oxygenase enzymes [abstract]. Br J Clin Pharmacol 1991;32:658P.
11. Binnie CD, van Emde Boas W, Kasteleijn-Nolste-Trenite DGA, de Korte RA, Meijer JW, Meinardi H, et al. Acute effects of lamotrigine (BW430C) in persons with epilepsy. Epilepsia 1986;27:248-54.
12. Jawad S, Yuen WC, Peck AW, Hamilton MJ, Oxley JR, Richens A. Lamotrigine: single-dose pharmacokinetics and initial 1 week experience in refractory epilepsy. Epilepsy Res 1987;1:194-201.
13. Ramsay RE, Pellock JM, Garnett WR, Sanchez RM, Valakas AM, Wargin WA, et al. Pharmacokinetics and safety of lamotrigine (Lamictal) in patients with epilepsy. Epilepsy Res 1991;10:191-200.
14. Bourgeois BFD. Pharmacologic interactions between valproate and other drugs. Am J Med 1988;84(suppl 1A):29-33.
15. Magdalou J, Herber R, Bidault R, Siest G. In vitro N-glucuronidation of a novel antiepileptic drug, lamotrigine, by human liver microsomes. J Pharmacol Exp Ther 1992;260:1166-73.
16. Levy RH. Variability in level-dose ratio of valproate: monotherapy vs polytherapy. Epilepsia 1984;25(suppl 1):S10-3.
17. Dreifuss FE, Santilli N, Langer DH, Sweeny KP, Moline KA, Menander KB. Valproic acid hepatic fatalities: a retrospective review. Neurology 1987;37:379-85.
18. Kesterson JW, Granneman GR, Machinist JM. The hepatotoxicity of valproic acid and its metabolites in rats; I: toxicologic, biochemical and histopathologic studies. Hepatology 1984;4:1143-52.
19. Kingsley E, Gray PD, Tolman KG, Tweedale R. The toxicity of the metabolites of sodium valproate in cultured hepatocytes. J Clin Pharmacol 1982;23:178-85.
20. Anderson GD, Acheampong AA, Wilensky AJ, Levy RH. Effect of valproate dose on formation of hepatotoxic metabolites. Epilepsia 1992;33:736-42.
21. Rettie AE, Rettenmeier AW, Howald WN, Baillie TA. Cytochrome P450 catalyzed formation of Δ-valproate, a toxic metabolite of valproic acid. Science 1987;235: 890-3.
22. Levy RH, Rettenmeier AW, Anderson GD, Wilensky AJ, Friel PN, Baillie TA, et al. Effects of polytherapy with phenytoin, carbamazepine, and stiripentol on formation of 4-ene-valproate, a hepatotoxic metabolite of valproic acid. Clin Pharmacol Ther 1990;48: 225-34.
23. Yuen AWC, Land G, Weatherly BC, Peck AW. Sodium valproate acutely inhibits lamotrigine metabolism. Br J Clin Pharmacol 1992;33:511-3.
24. Wolf P. Lamotrigine: preliminary clinical observations on pharmacokinetics and interactions with traditional antiepileptic drugs. J Epilepsy 1992;5:73-9.
25. Sailstad JM, Findlay JWA. Immunofluorometric assay for lamotrigine (Lamictal) in human plasma. Ther Drug Monit 1991;13:433-42.
26. Semmes RLO, Shen DD. Capillary gas chromatographic assay for valproic acid and its 2-desaturated metabolite in brain and plasma. J Chromatogr 1988; 432:185-97.
27. Rettenmeier AW, Howald WN, Levy RH, Witek DJ, Gordon WP, Porubek DJ, et al. Quantitative metabolic profiling of valproic acid in humans using automated gas chromatographic/mass spectrometric techniques. Biomed Environ Mass Spectrom 1989;18: 192-9.
28. Metzler CM, Elfring GL, McEwen AJ. A package of computer programs for pharmacokinetic modeling. Biometrics 1974;30:562.
29. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker, 1982.
30. Levy RH, Shen DD. In: Levy RH, Dreifuss FE, Mattson RH, Meldrum MB, Penry JK, editors. Antiepileptic drugs. New York: Raven Press, 1989:643-51.
31. Baillie TA, Rettenmeier AW. Valproate: biotransformation. In: Levy RH, Dreifuss FE, Mattson RH, Meldrum MB, Penry JK, editors. Antiepileptic drugs. New York: Raven Press, 1989:601-19.
32. Yau MK, Wargin WA, Wolf KB, Lai AA, Dren AT, Harris SI, et al. Effect of valproate on the pharmacokinetics of lamotrigine (Lamictal) at steady state [abstract]. Epilepsia 1992;33(suppl 3):82.
33. Yau MK, Adams MA, Wargin WA, Lai AA. A single-dose and steady-state pharmacokinetic study of lamotrigine in healthy male volunteers. Presented at the Third International Cleveland Clinic-Bethel Epilepsy Symposium on Antiepileptic Drug Pharmacology, June 1992.
34. Cohen AF, Land GS, Breimer DD, Yuen WC, Winton C, Peck AW. Lamotrigine, a new anticonvulsant: Pharmacokinetics in normal humans. Clin Pharmacol Ther 1987;42:535-41.
35. Fisher JE, Nau H, Loscher W. Alterations in the renal excretion of valproate and its metabolites after chronic treatment. Epilepsia 1991;32:146-50.